In the article titled “The Utility of Ovotransferrin and Ovotransferrin-Derived Peptides as Possible Candidates in the Clinical Treatment of Cardiovascular Diseases” [
Due to the rapid development of biomedicine, many nonconquerable diseases have been alleviated and treated in varying degrees. But inevitably, synthetic drugs have side effects, and there is a strong interest in finding new bioactive substances as potential candidates for treatment. Bioactive peptides exert systemic effects by entering the circulation via the intestinal tract or produce local effects in the gastrointestinal tract. But the most important thing is that it enhances health and safety profiles and may be a candidate for cardiovascular disease treatment [49]. The causes of cardiovascular disease are diverse, such as lifestyle habits, eating habits, and many congenital causes, which plague people’s normal life. Studies have shown that ovotransferrin and ovotransferrin-derived peptides could be anti-inflammatory, anti-oxidatory, and inhibit ACE to ease the development of cardiovascular disease (Table
The regulators of ovotransferrin and ovotransferrin-derived peptides and adjusting effect.
Bioactive peptide | Regulated factor | The result of adjustment | Reference |
---|---|---|---|
IRW | Angiotensin II | Inhibited the migration of vascular smooth muscle cells | [52] |
IRW | ACE inhibition and endothelial nitric oxide synthase | Antihypertensive effects | [45] |
IRW and IQW | Tumor necrosis factor (TNF) | Reducing endothelial inflammation and oxidative stress | [43] |
Ovotransferrin | Reactive oxygen species | Antioxidants and oxygen radical-scavenging effects | [53] |
IRW | ACE2, ICAM-1, and VCAM-1 | Increased ACE2 and decreased proinflammatory genes expression | [31] |
In addition, the following references should have been included in the references list of the original article [ Erdmann et al. [ Yu et al. [ Seppo et al. [ Liao et al. [ Huang et al. [